NCT00343356 is a Phase 2 clinical trial of Trement in Bladder Neoplasms, sponsored by LanZhou University.

Who is sponsoring NCT00343356?

NCT00343356 is sponsored by LanZhou University.

What drugs are being tested in NCT00343356?

Interventions in NCT00343356: Trement.

What condition does NCT00343356 study?

NCT00343356 studies Bladder Neoplasms.

Is NCT00343356 still recruiting?

NCT00343356 is currently completed. Last updated 21 June 2006.

Last reviewed 2006-06-21 · How we verify

NCT00343356

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study of Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder After Surgical Management

Completed Phase 2 Last updated 21 June 2006

What this trial tests

Phase 2 trial testing Trement in Bladder Neoplasms in 138 participants. Completed in 1 July 2003.

Timeline

1 June 1996

1 July 2003

Quick facts

Lead sponsor	LanZhou University
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	138
Start date	1 June 1996
Estimated completion	1 July 2003

Drugs / interventions tested

Trement — full drug profile →

Conditions studied

Bladder Neoplasms — all drugs for Bladder Neoplasms →

Sponsor

LanZhou University

Who can join

Adults 26 to 72, any sex, with Bladder Neoplasms. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Recurrence rate

Sponsor's own description

Biochemotherapy (combined immunotherapeutic drugs and chemotherapeutic drugs) has shown virtue than that use chemical or biological drugs alone in the treatment of some malignant tumor. Here we investigated the efficacy of sequential intravesical therapy with EPI and BCG to EPI or BCG alone in patients with transitional cell carcinoma of bladder cancer after surgical management.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Bladder Neoplasms

Currently open trials in the same condition.

NCT05072600 — Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer · Phase 2 · recruiting

Other LanZhou University trials

Trials by the same sponsor.

NCT07312370 — Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing · Phase 4 · not yet recruiting
NCT07263867 — Enhanced Ward Rounds for Bowel Preparation Quality in Hospitalized Patients Undergoing Colonoscopy · NA · not yet recruiting
NCT07314554 — Recurrence After Gastric and Intestinal Polyp Resection · not yet recruiting
NCT07286877 — Enhanced Ward Rounds and Communication for Pre-procedural Anxiety in GI Endoscopy Patients · NA · not yet recruiting
NCT07234344 — A Predictive Model for Midwives' C F: A Cross-Sectional Study · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00343356 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by LanZhou University
Last refreshed: 21 June 2006

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00343356.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing